Last reviewed · How we verify
Krystal Biotech, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| KB803 | KB803 | phase 3 | Gene therapy | COL7A1 gene | Dermatology / Rare Genetic Disorders | |
| Topical Beremagene Geperpavec | Topical Beremagene Geperpavec | phase 3 | Gene therapy | Dermatology |
Therapeutic area mix
- Dermatology · 1
- Dermatology / Rare Genetic Disorders · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abeona Therapeutics, Inc · 1 shared drug class
- AskBio Inc · 1 shared drug class
- BioLab 612 LLC · 1 shared drug class
- Brain Neurotherapy Bio, Inc. · 1 shared drug class
- Emily de los Reyes · 1 shared drug class
- Eva Morava-Kozicz · 1 shared drug class
- Kolon TissueGene, Inc. · 1 shared drug class
- 4D Molecular Therapeutics · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Krystal Biotech, Inc.:
- Krystal Biotech, Inc. pipeline updates — RSS
- Krystal Biotech, Inc. pipeline updates — Atom
- Krystal Biotech, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Krystal Biotech, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/krystal-biotech-inc. Accessed 2026-05-16.